NAMRU EURAFCENT Partners with Seek Labs to Advance Field-Deployable Technologies for Warfighter Readiness
These collaborations focus on advancing field-deployable diagnostic and therapeutic countermeasures that support force health protection and warfighter readiness.
Under a four-year agreement, NAMRU EURAFCENT will employ Seek Labs’ diagnostic and therapeutic platforms in operational environments, leveraging its expertise in clinical research and biosurveillance to deliver field-ready capabilities.
“This collaboration is a clear example of how we are actively working to deliver scalable, field-ready solutions for the fleet and joint force,” said Capt. Michael Prouty, commanding officer of NAMRU EURAFCENT. “Integrating these advanced technologies allows NAMRU EURAFCENT to enhance warfighter health, sustain operational effectiveness, and ensure our deployed personnel are protected from emerging health threats across the globe.”
These capabilities are intended for forward environments, where rapid detection and effective treatment of infectious diseases can directly impact mission execution, safeguard deployed personnel and maintain operational readiness. They are specifically designed for use by U.S. military medical teams operating in resource-constrained operational environments.
The ability to identify emerging health threats in a timely manner enables senior leadership and medical personnel to make informed decisions that enhance force protection.
“In the remote and often austere settings where our forces operate, having a rapid, reliable and field-deployable diagnostic capability is not just an advantage,” said Prouty, “it is a necessity for maintaining mission readiness and operational effectiveness.”
By integrating emerging technologies with operational research expertise, the collaboration aims to deliver scalable, field-ready solutions that enable the command to contribute directly to warfighter health protection and sustain operational effectiveness in diverse and challenging environments.
BioSeeker is Seek Labs’ artificial intelligence/machine learning (AI/ML)-guided sequence intelligence engine designed to accelerate both diagnostic and therapeutic development. This technology identifies highly stable, essential genetic regions that are critical to pathogens’ survival and integrates these findings into a continuously evolving library of vital disease targets. Outputs can be advanced through the Programmable Target Ablation Platform (PTAP), which is designed to disrupt pathogen replication and support immune-assisted clearance.
“SeekIt was engineered to collapse molecular testing from a laboratory workflow into a field decision,” said Jared Bauer, CEO and co-founder of Seek Labs. “What makes NAMRU EURAFCENT so valuable is that they bring the operational truth: which threats matter, where decisions break down and what a capability must do to earn its place with the warfighter. That perspective allows us to shape BioSeeker, SeekIt and PTAP around actual mission demands and move with greater confidence from promising technology toward validated, deployable capability.”
Seek Laboratories, Inc., based in Salt Lake City, Utah, develops field-deployable technology for health challenges with potential applications for force health protection and warfighter readiness.
NAMRU EURAFCENT, part of Navy Medicine Research & Development, conducts research, surveillance and studies of vaccines, therapeutic agents, diagnostic assays and vector control measures in the EUCOM, AFRICOM and CENTCOM Areas of Responsibility to better prevent and treat infectious diseases in support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
